The pre-clinical animal models often fail to predict intrinsic and idiosyncratic drug induced
liver injury (DILI), thus contributing to drug failures in clinical trials, black box warnings and …

Bioengineering an in vitro liver model recapitulating the native liver microarchitecture
consisting of parenchymal and non-parenchymal cells is crucial in achieving cellular …

Induced hepatic (iHep) cells generated by direct reprogramming have been proposed as
cell sources for drug screening and regenerative medicine. However, the practical use of a …

Drug-induced liver injury (DILI) remains a major cause of drug attrition, black-box warnings
on marketed drugs, and acute liver failures. It is clear with several high-profile drug failures …

DILI is a major cause of attrition in drug development with over 1000 FDA-approved drugs
known to potentially cause DILI in humans. Unfortunately, DILI is often not detected until …

In vitro drug-induced liver injury (DILI) models are promising tools for drug development to
predict adverse events during clinical usage. However, the currently available DILI models …

Drug-induced liver injury (DILI) is a leading cause of drug attrition, which is partly due to
differences between preclinical animals and humans in metabolic pathways. Therefore, in …

Three-dimensional (3D) bioprinting is a promising technology to establish a 3D in vitro
hepatic model that holds great potential in toxicological evaluation. However, in current …

The liver is the largest internal organ of the body with complex microarchitecture and
function that plays critical roles in drug metabolism. Hepatotoxicity and drug-induced liver …

In vitro liver models allow the investigation of the cell behavior in disease conditions or in
response to changes in the microenvironment. A major challenge in liver tissue engineering …